SLPI Antibody | 4249

SLPI Antibody | 4249 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: N/A

Immunogen: SLPI antibody was raised against a 17 amino acid synthetic peptide from near the center of human SLPI.
The immunogen is located within amino acids 60 - 110 of SLPI.

Research Area: Innate Immunity

Tested Application: E, WB, IHC-P

Application: SLPI antibody can be used for detection of SLPI by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1224 - Daudi Cell Lysate

Positive Control 2: Cat. No. 1402 - Mouse Lung Tissue Lysate

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 15 kDa
Observed: 19 kDa

Validation: N/A

Isoform: N/A

Purification: SLPI Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: SLPI Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: SLPI antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: SLPI Antibody: ALP, MPI, ALK1, BLPI, HUSI, WAP4, WFDC4, HUSI-I, Antileukoproteinase, ALP

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: SLPI Antibody: Secretory leukocyte protease inhibitor (SLPI) is produced at mucosal surfaces, primarily the upper respiratory tract and is thought to play an important role in the antiprotease defense mechanism of the lung. SLPI forms inhibitory complexes with numerous proteolytic enzymes such as neutrophil elastase, and has been shown to possess anti-inflammatory, anti-viral, and antibacterial activities. Its expression in oral epithelial cells is stimulated by HIV-1 gp120, suggesting that SLPI is a component of the oral mucosal response to HIV-1. In peripheral blood monocytes, SLPI can inhibit NF-κB activation by inhibiting IκB degradation in the cytoplasm and competing for NF-κB binding sites in the nucleus. This attenuation of the inflammatory response may also act to suppress liver metastases and other cancer cell invasions, but promote blood-borne metastasis via an invasion-independent pathway.